Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06016179 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Study acronym: RIOT2
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 22, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 70 words
    • Study description expanded, about 56 words
    • Site contact updated
    v6
  2. Primary completion date: Dec 2024 to Jan 2026v5 Show 4 more changesShow less
    • Start date: Nov 29, 2023 to Jan 30, 2024
    • Study completion date: Dec 2025 to Jan 2027
    • Site contact updated
    • Eligibility criteria shortened, about 1 word
  3. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Dec 2023 to Dec 2024
    • Study completion date: Dec 2024 to Dec 2025
    • Start date changed from estimate of Nov 23, 2023 to Nov 29, 2023
    • Site details revised
  4. Start date: Sep 2023 to Nov 23, 2023v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.
Trial Details
NCT Number NCT06016179
Lead Sponsor Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Conditions
(from sponsor)		 Malignant Pleural Effusion, Malignant Ascites
Related terms Pleural Effusion, Malignant
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov